A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
NCT04865770 on ClinicalTrials.gov · last registry update 2026-02-10
A small phase 3 — 106 participants, against a typical 424. The sponsor logged completion for 21 November 2024. Primary outcome, as filed: Change in Kidney Oxygenation (Cortex), Blood Oxygenation-level Dependent Magnetic Resonance Imaging (BOLD MRI) (R2*). semaglutide is already approved in the US for chronic kidney disease and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P3
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry
- Enrollment
- 106
- Started
- 2021-04-28
- Primary completion
- 2024-11-21 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in Kidney Oxygenation (Cortex), Blood Oxygenation-level Dependent Magnetic Resonance Imaging (BOLD MRI) (R2*)
Conditions studied
Diabetes Mellitus, Type 2 · Chronic Kidney Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.